VNRX
Price:
$0.645
Market Cap:
$61.90M
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
2012-03-02
Stock Exchange
AMEX
Ticker
VNRX
According to VolitionRx Limited’s latest financial reports and current stock price. The company's current PE Ratio is -1.79. This represents a change of -6.62% compared to the average of -1.92 of the last 4 quarters.
The mean historical PE Ratio of VolitionRx Limited over the last ten years is -6.42. The current -1.79 PE Ratio has changed 2.69% with respect to the historical average. Over the past ten years (40 quarters), VNRX's PE Ratio was at its highest in in the September 2023 quarter at -1.61. The PE Ratio was at its lowest in in the December 2014 quarter at -17.04.
Average
-6.42
Median
-6.25
Minimum
-11.59
Maximum
-1.45
Discovering the peaks and valleys of VolitionRx Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 267.26%
Maximum Annual PE Ratio = -1.45
Minimum Annual Increase = -67.46%
Minimum Annual PE Ratio = -11.59
Year | PE Ratio | Change |
---|---|---|
2023 | -1.45 | -67.46% |
2022 | -4.44 | -27.52% |
2021 | -6.13 | -28.71% |
2020 | -8.60 | -25.78% |
2019 | -11.59 | 267.26% |
2018 | -3.15 | -39.94% |
2017 | -5.25 | -40.63% |
2016 | -8.85 | 5.67% |
2015 | -8.37 | 31.24% |
2014 | -6.38 | -11.89% |
The current PE Ratio of VolitionRx Limited (VNRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.01
5-year avg
-6.44
10-year avg
-6.42
VolitionRx Limited’s PE Ratio is greater than electroCore, Inc. (-10.47), less than Conformis, Inc. (-0.32), greater than Evogene Ltd. (-3.02), greater than Evolus, Inc. (-12.34), less than OncoCyte Corporation (-0.69),
Company | PE Ratio | Market cap |
---|---|---|
-10.47 | $107.56M | |
-0.32 | $17.88M | |
-3.02 | $7.78M | |
-12.34 | $686.41M | |
-0.69 | $36.36M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like VolitionRx Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like VolitionRx Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is VolitionRx Limited's PE Ratio?
How is the PE Ratio calculated for VolitionRx Limited (VNRX)?
What is the highest PE Ratio for VolitionRx Limited (VNRX)?
What is the 3-year average PE Ratio for VolitionRx Limited (VNRX)?
What is the 5-year average PE Ratio for VolitionRx Limited (VNRX)?
How does the current PE Ratio for VolitionRx Limited (VNRX) compare to its historical average?